Gland Pharma Ltd. (IN:GLAND)
:GLAND
Top Page
Gland Pharma Ltd.
(GLAND)
Select Model
Select Model
Rating:61Neutral
Price Target:
₹1,821.00
▲(6.25% Upside)
Action:ReiteratedDate:12/02/25
The overall score of 61 for Gland Pharma Ltd. is primarily driven by strong financial performance, with a healthy balance sheet and solid profitability, though tempered by inconsistent revenue growth. Bearish technical indicators, reflecting a downward price trend and weak momentum, significantly weigh down the score. Valuation concerns due to a high P/E ratio also contribute to a cautious outlook.
Positive Factors
Strong Financial Health
The company's robust balance sheet and solid profitability metrics indicate financial stability, supporting long-term operational resilience and growth potential.
Negative Factors
Decline in Net Income
A decline in net income may signal challenges in maintaining profitability, potentially impacting future earnings and investment capacity.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Financial Health
The company's robust balance sheet and solid profitability metrics indicate financial stability, supporting long-term operational resilience and growth potential.
Read all positive factors
Gland Pharma Ltd. (GLAND) vs. iShares MSCI India ETF (INDA)
Market Cap
₹287.66B
Dividend Yield1.07%
Average Volume (3M)9.08K
Price to Earnings (P/E)27.1
Beta (1Y)0.61
Revenue Growth-1.51%
EPS Growth14.27%
CountryIN
Employees4,217
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)15.87
Shares Outstanding164,756,420
10 Day Avg. Volume10,062
30 Day Avg. Volume9,084
Financial Highlights & Ratios
PEG Ratio-3.82
Price to Book (P/B)2.80
Price to Sales (P/S)4.56
P/FCF Ratio48.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹2,165.00Price Target Upside26.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)73.16
Revenue Forecast (FY)₹72.50B
Gland Pharma Ltd. Business Overview & Revenue Model
Company Description
Gland Pharma Limited engages in the development, manufacture, and marketing of injectable-focused generic liquid parenteral products. The company's primary molecules include heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin inj...
How the Company Makes Money
Gland Pharma generates revenue primarily through the sale of its pharmaceutical products, particularly its complex injectables, which are sold in both domestic and international markets. The company's revenue model is driven by multiple key stream...
Gland Pharma Ltd. Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
85
Very Positive
Cash Flow
70
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 58.01B | 56.17B | 56.65B | 36.25B | 44.01B | 34.63B |
| Gross Profit | 24.00B | 31.54B | 31.11B | 17.65B | 21.51B | 18.53B |
| EBITDA | 14.22B | 12.31B | 12.97B | 10.31B | 15.10B | 13.02B |
| Net Income | 7.90B | 6.99B | 7.72B | 7.81B | 12.12B | 9.97B |
Balance Sheet | ||||||
| Total Assets | 118.00B | 112.25B | 106.61B | 87.78B | 78.34B | 64.96B |
| Cash, Cash Equivalents and Short-Term Investments | 27.04B | 29.52B | 19.39B | 37.63B | 32.43B | 30.03B |
| Total Debt | 3.02B | 3.14B | 3.72B | 44.53M | 47.43M | 49.95M |
| Total Liabilities | 22.37B | 20.74B | 19.37B | 8.19B | 6.76B | 5.93B |
| Stockholders Equity | 95.63B | 91.51B | 87.24B | 79.59B | 71.58B | 59.03B |
Cash Flow | ||||||
| Free Cash Flow | 3.99B | 5.30B | 6.07B | 1.41B | 2.69B | 3.76B |
| Operating Cash Flow | 5.93B | 9.15B | 9.97B | 3.64B | 7.91B | 6.05B |
| Investing Cash Flow | -923.82M | 17.05B | -17.57B | 12.08B | -10.03B | -15.24B |
| Financing Cash Flow | -3.79B | -4.33B | -7.99B | 149.19M | 348.98M | 12.38B |
Gland Pharma Ltd. Technical Analysis
Positive
1713.95
Price Trends
1751.77
Negative
1739.51
Negative
1829.33
Negative
Market Momentum
-7.42
Negative
53.92
Neutral
59.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GLAND, the sentiment is Positive. The current price of 1713.95 is above the 20-day moving average (MA) of 1670.08, below the 50-day MA of 1751.77, and below the 200-day MA of 1829.33, indicating a neutral trend. The MACD of -7.42 indicates Negative momentum. The RSI at 53.92 is Neutral, neither overbought nor oversold. The STOCH value of 59.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:GLAND.
Gland Pharma Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | ₹777.98B | 18.87 | ― | 0.33% | 7.33% | -3.79% | |
73 Outperform | ₹4.12T | 30.62 | ― | 0.91% | 9.26% | -5.47% | |
70 Outperform | ₹1.01T | 21.88 | ― | 0.63% | 14.10% | 9.72% | |
66 Neutral | ₹1.39T | 51.30 | ― | 0.84% | 9.11% | 18.76% | |
63 Neutral | ₹399.85B | 35.44 | ― | 2.16% | 4.17% | 41.51% | |
61 Neutral | ₹287.66B | 27.13 | ― | 1.07% | -1.51% | 14.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:GLAND
Gland Pharma Ltd.
1,746.00
364.27
26.36%
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,339.50
261.00
24.20%
IN:DRREDDY
Dr. Reddy's Laboratories Ltd.
1,212.35
110.19
10.00%
IN:GLAXO
GlaxoSmithKline Pharmaceuticals Limited
2,360.30
-351.46
-12.96%
IN:SUNPHARMA
Sun Pharmaceutical Industries Limited
1,717.35
81.30
4.97%
IN:TORNTPHARM
Torrent Pharmaceuticals Ltd
4,093.15
993.77
32.06%
Gland Pharma Ltd. Corporate Events
Gland Pharma Schedules Investor Meetings for November 2025
Oct 31, 2025
Gland Pharma Limited has announced a series of scheduled meetings with analysts and institutional investors in November 2025. These meetings, which include group and one-on-one sessions, are part of the company’s ongoing efforts to engage wi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.